Newsroom

The winners of National Institutes of Health’s 9th annual Design by Biomedical Undergraduate Teams (DEBUT) challenge developed simple and low-cost diagnostics and treatments for conditions such as tuberculosis, cervical cancer, birth defects, and onchocerciasis (river blindness).

NIBIB-funded researchers at NYU Langone Health worked with Facebook AI researchers to develop a method to speed up MRI scans.

NIBIB-funded researchers have developed a way to use artificial intelligence to speed up MRI imaging without sacrificing quality.

A team has developed a class of light-switchable, highly adaptable molecular tools with new capabilities to control cellular activities. The antibody-like proteins, called OptoBinders, have potential applications including protein purification, the improved production of biofuels, and new types of targeted cancer therapies.

Researchers demonstrated how a deep learning framework they call 'Brain-NET' can accurately predict a person's level of expertise in terms of their surgical motor skills, based solely on neuroimaging data.

NIH announced that AI technology is underway to aid physicians across the United States in the global war against COVID-19. These efforts are taking place with the Medical Imaging and Data Resource Center, which is comprised of research from physicists, physicians, radiologists, and scientists across the country. Read more at The Burgundy Zine.

NIBIB-funded researchers have created nanoparticles for successful gene therapy of a mouse model of macular degeneration. The nanoparticle carriers have the potential to significantly expand the effectiveness of gene therapies for human eye diseases, including blindness.

Brain tumors are typically diagnosed using MRI imaging because taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient’s poor health conditions. Researchers are developing a method to diagnose brain tumors without any incisions.

NIBIB mourns the passing of molecular imaging pioneer and NIBIB Advisory Council member, Sanjiv “Sam” Gambhir, M.D., Ph.D.